Foreign Portfolio Investment

Business

Motorpoint Group's Declining Returns on Capital Raise Concerns Among Investors

Motorpoint Group, the UK's largest independent car retailer, is showing signs of strain as its return on capital employed (ROCE) has fallen significantly over the past five years. While still above the industry average, the downward trend, coupled with rising current liabilities, suggests challenges ahead for the London-listed firm.

Jan 30, 2026

Business

Sentient (SENT) Bucks Crypto Downtrend with 60% Surge: The Metrics Behind the Rally and Looming Risks

As the broader cryptocurrency market stumbles, Sentient's SENT token has staged a remarkable 60% rally. A deep dive into on-chain and derivatives data reveals the drivers of its resilience—and the significant vulnerabilities that could threaten its gains.

Jan 30, 2026

Business

Analysts Flag LSL Property Services as Undervalued, Shares Trading at a Steep Discount

A new financial analysis suggests shares of UK property services group LSL could be trading at a significant discount to their estimated intrinsic value, presenting a potential opportunity for investors.

Jan 30, 2026

Business

Meritage Homes Navigates 'Softer' Housing Market, Prioritizes Margins Over Volume

Meritage Homes concluded a challenging 2025, citing affordability pressures and waning buyer confidence. While maintaining a cautious stance on incentives, the homebuilder is expanding its community footprint and boosting shareholder returns, betting on long-term demographic demand.

Jan 30, 2026

Business

Market Turbulence Creates Buying Opportunities: Three European Stocks Trading at a Discount

Amidst a backdrop of geopolitical tensions and market volatility, a closer look reveals resilient European companies whose current share prices may not reflect their underlying strength and future growth prospects.

Jan 30, 2026

Business

Insider Bets Signal Confidence in Select European Growth Stocks Amid Market Uncertainty

As the STOXX Europe 600 stumbles under geopolitical and trade pressures, a focus on companies with significant insider ownership reveals where leadership is putting its own capital on the line. We examine three firms where high insider stakes coincide with robust growth forecasts.

Jan 30, 2026

Business

Bitcoin Retreats Below $90K as $8.8 Billion Options Expiry Looms, Testing Market Resilience

Bitcoin's struggle to hold the $90,000 level intensifies as a massive monthly options expiry approaches, driving traders toward defensive positioning and heightened volatility hedging.

Jan 30, 2026

Business

Vera Therapeutics Sees Major Price Target Hikes as Analysts Bet Big on Its Kidney Disease Drug

Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.

Jan 30, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

Analyst Cuts Pagaya Target But Stays Bullish Amid Strong Growth Metrics

Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.

Jan 30, 2026

Business

Analysts Bullish on Riot Platforms After Strategic AMD Data Center Deal

Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.

Jan 30, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

Analysts Bullish on Cipher Mining as Pivot to AI Infrastructure Gains Momentum

Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.

Jan 30, 2026

Business

Mizuho Lifts SanDisk Target to $600, Citing NAND Supply Crunch and AI-Driven Demand Surge

Mizuho Securities dramatically raised its price target on SanDisk, forecasting a severe NAND flash memory shortage driven by explosive AI server demand and constrained production capacity through 2027.

Jan 30, 2026

Business

DigitalOcean Soars as 'Clawdbot' AI Assistant Drives Analyst Optimism and Price Target Hikes

Bank of America leads a wave of analyst upgrades for DigitalOcean, citing the viral success of its AI agent 'Clawdbot' and the company's strategic positioning in the burgeoning agentic AI market for developers.

Jan 30, 2026

Business

Analysts See Deep Value in Corero Network Security, Suggesting Shares Could Be Undervalued by Over 40%

A new discounted cash flow analysis indicates Corero Network Security plc (LON:CNS) may be significantly undervalued at current trading levels, presenting a potential opportunity for investors in the cybersecurity sector.

Jan 30, 2026

Business

Apple Feels the Pinch: Global Memory Chip Shortage Begins to Bite Tech Giant

Despite record iPhone demand, Apple CEO Tim Cook warns that soaring memory chip costs are set to squeeze margins, highlighting a supply crisis gripping the entire tech industry.

Jan 30, 2026

Business

Gallagher Posts Strong Q4 Growth, Eyes M&A Expansion Amid Stable Casualty Market

Arthur J. Gallagher & Co. reported robust revenue growth exceeding 30% for the fourth quarter of 2025, driven by a healthy mergers and acquisitions pipeline and resilient performance in key sectors. Leadership expressed confidence in navigating a softening property insurance market while maintaining stable casualty pricing and talent retention.

Jan 30, 2026

Business

Deckers Outdoor Soars on HOKA and UGG Momentum, Raises Full-Year Outlook

Fueled by exceptional demand for its HOKA and UGG brands, Deckers Outdoor Corp. posted a robust third-quarter performance, prompting the company to raise its fiscal 2026 guidance. Executives pointed to strategic product launches, direct-to-consumer strength, and clean marketplace inventories as key drivers.

Jan 30, 2026

Business

ResMed Posts Strong Q2 Growth on New Product Momentum and GLP-1 Therapy Tailwinds

ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.

Jan 30, 2026